APMD
NASDAQ HealthcareApnimed, Inc. - Common Stock
Biotechnology
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
๐ Market Data
| Price | $32.55 |
|---|---|
| Volume | 516,312 |
| Market Cap | 1.30B |
| 52-Week High | $34.74 |
| 52-Week Low | $16.12 |
| P/E Ratio | 9.41 |
| Price / Book | -0.60 |
๐ฏ Investment Strategy Scores
APMD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (64/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Find APMD in your text
Paste any article, transcript, or post โ the tool will extract APMD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.